Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir

Luigia Rossi, Giorgio Brandi, Giuditta F. Schiavano, Emanuela Balestra, Enrico Millo, Sonia Scarfi, Gianluca Damonte, Anna Gasparini, Mauro Magnani, Carlo Federico Perno, Umberto Benatti, Antonio De Flora

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Human herpesvirus (HSVs) are distributed worldwide and are among the most frequent causes of viral infection in HIV-1-immunocompromised patients. Hence, therapeutic strategies able to inhibit HSV-1 and HIV-1 replication are sorely needed. Until now, the most common therapies against HSV-1 and HIV-1 infectivity have been based on the administration of nucleoside analogs; however, to be active, these antiviral drugs must be converted to their triphosphorylated derivatives by viral and/or cellular kinases. At the cellular level, the main problems involved in the use of such drugs are their limited phosphorylation in some cells (e.g., antiretroviral drugs in macrophages) and the cytotoxic side effects of nucleoside analog triphosphates. To overcome these limitations, a new heterodinucleotide (AZTp2ACV) consisting of both an antiretroviral and an antiherpetic drug, bound by a pyrophosphate bridge, was designed and synthesized. The impermeant AZTp2ACV was encapsulated into autologous erythrocytes modified to increase their recognition and phagocytosis by human macrophages. Once inside macrophages, metabolic activation of the drug occurred. The addition of AZTp2ACV-loaded erythrocytes to human macrophages provided effective and almost complete in vitro protection from HIV-1 and HSV-1 replications, respectively. Therefore, AZTp2ACV acts as an efficient antiviral prodrug following selective targeting to macrophages by means of loaded erythrocytes.

Original languageEnglish
Pages (from-to)435-444
Number of pages10
JournalAIDS Research and Human Retroviruses
Volume14
Issue number5
Publication statusPublished - Mar 20 1998

Fingerprint

Acyclovir
Zidovudine
Herpesviridae
Simplexvirus
HIV-1
Erythrocytes
Macrophages
HIV
Nucleosides
Pharmaceutical Preparations
Antiviral Agents
Macrophage Activation
Prodrugs
Immunocompromised Host
Virus Diseases
Phagocytosis
Phosphotransferases
Phosphorylation
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir. / Rossi, Luigia; Brandi, Giorgio; Schiavano, Giuditta F.; Balestra, Emanuela; Millo, Enrico; Scarfi, Sonia; Damonte, Gianluca; Gasparini, Anna; Magnani, Mauro; Perno, Carlo Federico; Benatti, Umberto; De Flora, Antonio.

In: AIDS Research and Human Retroviruses, Vol. 14, No. 5, 20.03.1998, p. 435-444.

Research output: Contribution to journalArticle

Rossi, L, Brandi, G, Schiavano, GF, Balestra, E, Millo, E, Scarfi, S, Damonte, G, Gasparini, A, Magnani, M, Perno, CF, Benatti, U & De Flora, A 1998, 'Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir', AIDS Research and Human Retroviruses, vol. 14, no. 5, pp. 435-444.
Rossi, Luigia ; Brandi, Giorgio ; Schiavano, Giuditta F. ; Balestra, Emanuela ; Millo, Enrico ; Scarfi, Sonia ; Damonte, Gianluca ; Gasparini, Anna ; Magnani, Mauro ; Perno, Carlo Federico ; Benatti, Umberto ; De Flora, Antonio. / Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir. In: AIDS Research and Human Retroviruses. 1998 ; Vol. 14, No. 5. pp. 435-444.
@article{f699ad5ef1ae44ad8a6dac9c292564be,
title = "Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir",
abstract = "Human herpesvirus (HSVs) are distributed worldwide and are among the most frequent causes of viral infection in HIV-1-immunocompromised patients. Hence, therapeutic strategies able to inhibit HSV-1 and HIV-1 replication are sorely needed. Until now, the most common therapies against HSV-1 and HIV-1 infectivity have been based on the administration of nucleoside analogs; however, to be active, these antiviral drugs must be converted to their triphosphorylated derivatives by viral and/or cellular kinases. At the cellular level, the main problems involved in the use of such drugs are their limited phosphorylation in some cells (e.g., antiretroviral drugs in macrophages) and the cytotoxic side effects of nucleoside analog triphosphates. To overcome these limitations, a new heterodinucleotide (AZTp2ACV) consisting of both an antiretroviral and an antiherpetic drug, bound by a pyrophosphate bridge, was designed and synthesized. The impermeant AZTp2ACV was encapsulated into autologous erythrocytes modified to increase their recognition and phagocytosis by human macrophages. Once inside macrophages, metabolic activation of the drug occurred. The addition of AZTp2ACV-loaded erythrocytes to human macrophages provided effective and almost complete in vitro protection from HIV-1 and HSV-1 replications, respectively. Therefore, AZTp2ACV acts as an efficient antiviral prodrug following selective targeting to macrophages by means of loaded erythrocytes.",
author = "Luigia Rossi and Giorgio Brandi and Schiavano, {Giuditta F.} and Emanuela Balestra and Enrico Millo and Sonia Scarfi and Gianluca Damonte and Anna Gasparini and Mauro Magnani and Perno, {Carlo Federico} and Umberto Benatti and {De Flora}, Antonio",
year = "1998",
month = "3",
day = "20",
language = "English",
volume = "14",
pages = "435--444",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir

AU - Rossi, Luigia

AU - Brandi, Giorgio

AU - Schiavano, Giuditta F.

AU - Balestra, Emanuela

AU - Millo, Enrico

AU - Scarfi, Sonia

AU - Damonte, Gianluca

AU - Gasparini, Anna

AU - Magnani, Mauro

AU - Perno, Carlo Federico

AU - Benatti, Umberto

AU - De Flora, Antonio

PY - 1998/3/20

Y1 - 1998/3/20

N2 - Human herpesvirus (HSVs) are distributed worldwide and are among the most frequent causes of viral infection in HIV-1-immunocompromised patients. Hence, therapeutic strategies able to inhibit HSV-1 and HIV-1 replication are sorely needed. Until now, the most common therapies against HSV-1 and HIV-1 infectivity have been based on the administration of nucleoside analogs; however, to be active, these antiviral drugs must be converted to their triphosphorylated derivatives by viral and/or cellular kinases. At the cellular level, the main problems involved in the use of such drugs are their limited phosphorylation in some cells (e.g., antiretroviral drugs in macrophages) and the cytotoxic side effects of nucleoside analog triphosphates. To overcome these limitations, a new heterodinucleotide (AZTp2ACV) consisting of both an antiretroviral and an antiherpetic drug, bound by a pyrophosphate bridge, was designed and synthesized. The impermeant AZTp2ACV was encapsulated into autologous erythrocytes modified to increase their recognition and phagocytosis by human macrophages. Once inside macrophages, metabolic activation of the drug occurred. The addition of AZTp2ACV-loaded erythrocytes to human macrophages provided effective and almost complete in vitro protection from HIV-1 and HSV-1 replications, respectively. Therefore, AZTp2ACV acts as an efficient antiviral prodrug following selective targeting to macrophages by means of loaded erythrocytes.

AB - Human herpesvirus (HSVs) are distributed worldwide and are among the most frequent causes of viral infection in HIV-1-immunocompromised patients. Hence, therapeutic strategies able to inhibit HSV-1 and HIV-1 replication are sorely needed. Until now, the most common therapies against HSV-1 and HIV-1 infectivity have been based on the administration of nucleoside analogs; however, to be active, these antiviral drugs must be converted to their triphosphorylated derivatives by viral and/or cellular kinases. At the cellular level, the main problems involved in the use of such drugs are their limited phosphorylation in some cells (e.g., antiretroviral drugs in macrophages) and the cytotoxic side effects of nucleoside analog triphosphates. To overcome these limitations, a new heterodinucleotide (AZTp2ACV) consisting of both an antiretroviral and an antiherpetic drug, bound by a pyrophosphate bridge, was designed and synthesized. The impermeant AZTp2ACV was encapsulated into autologous erythrocytes modified to increase their recognition and phagocytosis by human macrophages. Once inside macrophages, metabolic activation of the drug occurred. The addition of AZTp2ACV-loaded erythrocytes to human macrophages provided effective and almost complete in vitro protection from HIV-1 and HSV-1 replications, respectively. Therefore, AZTp2ACV acts as an efficient antiviral prodrug following selective targeting to macrophages by means of loaded erythrocytes.

UR - http://www.scopus.com/inward/record.url?scp=17144467334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144467334&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 435

EP - 444

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -